Edition:
United States

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

5.99USD
14 Aug 2018
Change (% chg)

-- (--)
Prev Close
$5.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
70,444
52-wk High
$6.86
52-wk Low
$2.02

Chart for

About

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $278.23
Shares Outstanding(Mil.): 45.09
Dividend: --
Yield (%): --

Financials

  ADMA.OQ Industry Sector
P/E (TTM): -- 169.61 31.56
EPS (TTM): -1.69 -- --
ROI: -67.57 1.42 12.88
ROE: -152.96 0.52 15.04

BRIEF-ADMA Biologics Files For Mixed Shelf Offering Of Up To $100 Mln

* ADMA BIOLOGICS FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source http://bit.ly/2IrSugh Further company coverage:

May 18 2018

BRIEF-Adma Biologics Granted U.S. Patent For Treating Respiratory Infections

* ADMA BIOLOGICS GRANTED U.S. PATENT FOR TREATING RESPIRATORY INFECTIONS

May 16 2018

BRIEF-ADMA Biologics Q1 Loss Per Share $0.39

* ADMA BIOLOGICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-ADMA Biologics Retires About 8.6 Million Shares Previously Issued to Biotest

* ADMA BIOLOGICS INC - RETIRES APPROXIMATELY 8.6 MILLION SHARES PREVIOUSLY ISSUED TO BIOTEST PHARMACEUTICALS CORPORATION AND ITS FORMER PARENT, BIOTEST AG

May 14 2018

BRIEF-ADMA Biologics Releases Its First Commercial Batch Of Nabi-HB Manufactured Under Its Ownership

* ADMA BIOLOGICS ANNOUNCES THE RELEASE OF ITS FIRST COMMERCIAL BATCH OF NABI-HB MANUFACTURED UNDER ITS OWNERSHIP

Apr 24 2018

Competitors

  Price Chg
Baxter International Inc (BAX.N) $70.71 0.00
Biotest AG (BIOG.DE) €24.05 --
Biotest AG (BIOG_p.DE) €23.50 --

Earnings vs. Estimates